Los Angeles Capital Management LLC Has $2.89 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Los Angeles Capital Management LLC lifted its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 33.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 123,401 shares of the biopharmaceutical company’s stock after buying an additional 31,124 shares during the period. Los Angeles Capital Management LLC’s holdings in TG Therapeutics were worth $2,886,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. NBC Securities Inc. grew its position in TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 485 shares during the last quarter. Blue Trust Inc. grew its position in TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 849 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new position in TG Therapeutics during the second quarter valued at about $35,000. ORG Wealth Partners LLC acquired a new position in TG Therapeutics in the 3rd quarter valued at approximately $53,000. Finally, Values First Advisors Inc. bought a new stake in shares of TG Therapeutics in the 3rd quarter worth approximately $58,000. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

TG Therapeutics stock opened at $30.91 on Wednesday. TG Therapeutics, Inc. has a 52-week low of $9.81 and a 52-week high of $32.48. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The stock has a fifty day moving average price of $24.15 and a two-hundred day moving average price of $20.79. The firm has a market capitalization of $4.79 billion, a P/E ratio of -309.07 and a beta of 2.19.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.65%. The company’s revenue for the quarter was down 49.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.73 earnings per share. As a group, analysts anticipate that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TGTX has been the topic of a number of research reports. TD Cowen assumed coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective on the stock. B. Riley boosted their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. HC Wainwright raised their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Finally, The Goldman Sachs Group lifted their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

Insider Activity

In related news, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the sale, the director now directly owns 100,195 shares of the company’s stock, valued at $3,049,935.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.50% of the stock is currently owned by corporate insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.